Editorial Director, OncLive
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com
FDA Approves Bi-weekly Teclistamab Dosing for Relapsed/Refractory Multiple Myeloma
February 20th 2024The FDA has approved a supplemental Biologics License Application for teclistamab-cqyv (Tecvayli) at a reduced dose of 1.5 mg/kg every 2 weeks in patients with relapsed/refractory multiple myeloma who have achieved and maintained a complete response or greater for at least 6 months.
Read More
FDA Approves Delivery System of Biosimiliar Pegfilgrastim-cbqv for Febrile Neutropenia
December 26th 2023The FDA has approved an on-body injector (OBI) presentation of the biosimilar pegfilgrastim-cbqv biosimilar (Udencya), known as Udencya Onbody, which is administered to patients with cancer the day after chemotherapy in order to decrease infection incidence from febrile neutropenia.
Read More
The presence of ESR1 coabnormalities, including TP53 and PIK3CA mutations, and CCND1 and FGFR1 amplification, did not demonstrate a negative impact on the efficacy with lasofoxifene and abemaciclib in patients with estrogen receptor–positive, ESR1-mutant metastatic breast cancer.
Read More
Quality of Life, Toxicity Weighed Most by Patients When Choosing Metastatic Breast Cancer Treatment
December 20th 2023Quality of life and adverse effects are key components most patients with estrogen receptor–positive, HER2-negative metastatic breast cancer weigh when choosing an anticancer therapy, according to patient-reported results of an ESR1 QUAlity of Life Survey 3 survey.
Read More
FDA Approves Eflornithine for Adult, Pediatric Patients With High-Risk Neuroblastoma
December 13th 2023The FDA has approved eflornithine (Iwilfin) as a treatment to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma who have achieved at least a partial response to prior multi-agent, multimodality therapy including anti-GD2 immunotherapy.
Read More
Pelabresib/Ruxolitinib Combo Improves Splenomegaly, TSS in JAK Inhibitor–Naive Myelofibrosis
December 11th 2023Pelabresib plus ruxolitinib demonstrated a 35% or greater reduction in spleen volume and trended toward reducing mean absolute total symptom score (TSS) as well as improving TSS reduction by 50% at 24 weeks in patients with JAK inhibitor–naive myelofibrosis.
Read More
Orca-T Shows High Survival Rates in Intermediate-/High-Risk Myelodysplastic Syndrome
December 10th 2023The high-precision cell therapy Orca-T demonstrated high rates of relapse-free survival, overall survival, and graft-vs-host disease RFS at 1 year, as well as a low incidence of GVHD in patients with intermediate- to high-risk myelodysplastic syndrome.
Read More
Revumenib Combo Showcases Early Activity in Relapsed/Refractory AML
December 9th 2023Revumenib, decitabine/cedazuridine, plus venetoclax elicited an objective response rate of 100% with acceptable safety in patients with relapsed/refractory acute myeloid leukemia enrolled in the small phase 1/2 SAVE study.
Read More
Neoadjuvant pembrolizumab combined with chemotherapy followed by adjuvant pembrolizumab compared with placebo plus chemotherapy continued to show a clinically meaningful improvement in event-free survival in patients with high-risk, early-stage triple-negative breast cancer.
Read More
Maintenance Pembrolizumab/Olaparib Misses Survival End Points in Locally Advanced or Metastatic TNBC
December 6th 2023Pembrolizumab plus olaparib did not improve progression-free or overall survival vs pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer who received induction pembrolizumab plus chemotherapy.
Read More
Early Use of ctDNA May Accelerate Time to Treatment and Improve Survival in NSCLC
November 11th 2023While there are considerable barriers to incorporating comprehensive genotyping, the use of circulating tumor DNA offers an improvement in molecular testing—and doing so earlier can accelerate the time to treatment and improve survival for patients with lung cancer.
Read More
FDA Approves Fruquintinib for Metastatic Colorectal Cancer
November 8th 2023The FDA has approved fruquintinib (Fruzaqla) for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
Read More
BXCL701/Pembrolizumab Combo Prolongs OS in mCRPC of Adenocarcinoma Phenotype
November 8th 2023Treatment with the oral innate immune activator BXCL701 combined with pembrolizumab demonstrated prolonged overall survival in patients with metastatic castration-resistant prostate cancer of adenocarcinoma phenotype.
Read More
Selpercatinib Significantly Improves PFS, Responses in Advanced RET+ Medullary Thyroid Cancer
October 21st 2023Selpercatinib resulted in a statistically significant improvement in progression-free survival and overall response rate compared with cabozantinib or vandetanib in patients with advanced, multikinase inhibitor–naïve, RET-mutant medullary thyroid cancer, according to interim findings from the phase 3 LIBRETTO-531 trial.
Read More
FDA Approves Glofitamab-gxbm for Relapsed/Refractory DLBCL
June 16th 2023The FDA has approved glofitamab-gxbm (Columvi) for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after two or more lines of systemic therapy.
Read More